ClinicalTrials.gg
CompletedNCT00443820Updated Apr 19, 2011Results posted

Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

A Phase 3 interventional study of terbinafine and Placebo in Onychomycosis, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in 3 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
526
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing terbinafine in Onychomycosis — 1 open to participants now, 2 under way, 1 of them phase 3. Terbinafine · Onychomycosis.

Enrollment
3rd of 19
526 · median 100
Started
2006
with 1 other
Phase 3
10 of 20
none open now
Registered
1st of 20
by date
Lead sponsor
2 of 20
Novartis Pharmaceuticals

Among the 20 studies testing terbinafine in Onychomycosis, this one is the 3rd largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2006, is one of 10 in phase 3, and was the 1st registered.

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

Browse Onychomycosis studies →

Open to participants now

1 of the 20 studies testing terbinafine in Onychomycosis is open now. Recruiting first, the newest first:

About terbinafine

Terbinafine: first FDA approval 1992 (LAMISIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing terbinafine in Onychomycosis, or all of them as a file.
02

Study summary

This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.

03

Conditions studied

  • Onychomycosis

Browse trials for

Keywords

  • Toenail fungus
  • Onychomycosis
  • Nail fungus
  • Toenail fungal infection
  • Tinea unguium
  • Dermatophytes
  • Foot dermatoses
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and females 12 - 75 years of age
  • Fungal toenail infection of one or both of the large (great) toenails
  • The nail infection must be due to a dermatophyte, (mixed infections dermatophyte and non-dermatophyte] are not allowed)

Exclusion criteria

Exclusion Criteria:

  • Target foot must not have severe plantar (moccasin) tinea pedis that would require systemic therapy. Mild to moderate tinea pedis (athlete's foot) infection should be treated with terbinafine prior to baseline or at any time during the trial. Other topical treatments for athlete's foot may be recommended at the discretion of the investigator.
  • Subjects must not have abnormalities of the nail that could prevent a normal appearing nail if clearing of infection is achieved
  • No administration of systemic antifungal medications within 6 months prior to screening visit
  • No application of prescription topical antifungal medications for toenail fungus within 3 months or other commercially available topical medications for toenail fungus applied directly to the toenails within 1 month prior to screening visit
  • No professional pedicures or application of any nail polish product or nail cosmetic to the toenails after the screening visit
  • Known pregnancy or lactation at time of enrollment

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
526 participants (actual)

Study arms

  • Experimental
    1

    Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks

    Drug: terbinafine

  • Placebo comparator
    2

    Vehicle (placebo) for 48 weeks

    Drug: Placebo

  • Experimental
    3

    Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks

    Drug: terbinafine

  • Placebo comparator
    4

    Vehicle (placebo) for 24 weeks

    Drug: Placebo

Interventions

  • Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks

    Also known as: Lamisil

  • DrugPlacebo

    Vehicle (placebo) once daily for 48 weeks

  • Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks

    Also known as: Lamisil

  • DrugPlacebo

    Vehicle (placebo) once daily for 24 weeks

06

What researchers measure

Primary outcomes

  1. Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks

    Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.

    Time frame: 52 weeks

Secondary outcomes

  1. Efficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks

    Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes.

    Time frame: 52 weeks

  2. Efficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks

    Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and \<= 10% residual involvement of the target toenail. Clinical effectiveness was a composite binary variable defined as "Yes" if: * If mycological cure (negative KOH and negative culture for dermatophytes) and * = 10% residual involvement of the target toenail "No" if otherwise

    Time frame: 52 weeks

  3. Safety and Tolerability Assessed by the Number of Participants With Adverse Events

    Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE and death. Additional details can be found in the Adverse Event Section.

    Time frame: 52 weeks

07

Results

Posted Apr 19, 2011

Participant flow

This randomized, double -blind, vehicle -controlled, multicenter, parallel group study was designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine hydrogen chloride 10% topical solution (TTS10%) applied daily in patients with toenail onychomycosis. Started 07 DEC 2006 and ending 27 JUN 2008.

Participant flow — Overall Study
MilestoneTerbinafine 24 WeeksVehicle 24 WeeksTerbinafine 48 WeeksVehicle 48 Weeks
Started133130135128
Safety population131129134126
Completed112111117111
Not completed21191817
Withdrew: Adverse event1100
Withdrew: Lack of efficacy3211
Withdrew: Protocol violation2121
Withdrew: Withdrawal by subject6789
Withdrew: Lost to follow-up9865
Withdrew: Administrative problems0001
Withdrew: Death0010

Outcome measures

PrimaryEfficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks

Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.

Time frame:
52 weeks
Reported as:
Number · Percentage of participants
Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks
Percentage of participantsTerbinafine 24 WeeksVehicle 24 WeeksTerbinafine 48 WeeksVehicle 48 Weeks
Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks1.50 (-1.82 to 3.29)0.77 (-1.82 to 3.29)2.96 (0.10 to 5.82)0 (0.10 to 5.82)
SecondaryEfficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks

Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes.

Time frame:
52 weeks
Reported as:
Number · Percentage of participants
Efficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks
Percentage of participantsTerbinafine 24 WeeksVehicle 24 WeeksTerbinafine 48 WeeksVehicle 48 Weeks
Efficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks15.04 (1.54 to 16.23)6.15 (1.54 to 16.23)22.22 (6.00 to 22.82)7.81 (6.00 to 22.82)
SecondaryEfficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks

Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and \<= 10% residual involvement of the target toenail. Clinical effectiveness was a composite binary variable defined as "Yes" if: * If mycological cure (negative KOH and negative culture for dermatophytes) and * = 10% residual involvement of the target toenail "No" if otherwise

Time frame:
52 weeks
Reported as:
Number · Percentage of participants
Efficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks
Percentage of participantsTerbinafine 24 WeeksVehicle 24 WeeksTerbinafine 48 WeeksVehicle 48 Weeks
Efficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks3.010.775.930.78
SecondarySafety and Tolerability Assessed by the Number of Participants With Adverse Events

Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE and death. Additional details can be found in the Adverse Event Section.

Time frame:
52 weeks
Reported as:
Number · Number of participants
Safety and Tolerability Assessed by the Number of Participants With Adverse Events
Number of participantsTerbinafine 24 WeeksVehicle 24 WeeksTerbinafine 48 WeeksVehicle 48 Weeks
At least 1 AE80729487
At least 1 SAE8397
Study drug discontinued due to an AE0110
Death0010

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Terbinafine 24 Weeks—8/131 (6.1%)37/131 (28.2%)
Vehicle 24 Weeks—3/129 (2.3%)38/129 (29.5%)
Terbinafine 48 Weeks—9/134 (6.7%)54/134 (40.3%)
Vehicle 48 Weeks—7/126 (5.6%)52/126 (41.3%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventTerbinafine 24 WeeksVehicle 24 WeeksTerbinafine 48 WeeksVehicle 48 Weeks
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1310/1290/1340/126
TachycardiaCardiac disorders0/1310/1290/1341/126
ConstipationGastrointestinal disorders0/1310/1290/1341/126
PneumoniaInfections and infestations0/1310/1290/1341/126
HypocalcaemiaMetabolism and nutrition disorders0/1310/1290/1341/126
Back painMusculoskeletal and connective tissue disorders0/1310/1291/1341/126
Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1310/1290/1341/126
SciaticaNervous system disorders0/1310/1290/1341/126
Bladder prolapseRenal and urinary disorders0/1310/1290/1341/126
DysuriaRenal and urinary disorders0/1310/1290/1341/126
Most frequent other events
Most frequent other events
EventTerbinafine 24 WeeksVehicle 24 WeeksTerbinafine 48 WeeksVehicle 48 Weeks
HeadacheNervous system disorders21/13121/12928/13423/126
NasopharyngitisInfections and infestations13/13111/12915/13415/126
InfluenzaInfections and infestations2/1311/12913/13410/126
Back painMusculoskeletal and connective tissue disorders8/1317/1296/13412/126
Upper respiratory tract infectionInfections and infestations4/1314/1294/13410/126
HypertensionVascular disorders1/1313/1298/1344/126
SinusitisInfections and infestations3/1310/1294/1347/126

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Terbinafine 24 WeeksVehicle 24 WeeksTerbinafine 48 WeeksVehicle 48 WeeksTotal
<=18 years00011
Between 18 and 65 years931039597388
>=65 years40274030137
Sex: Female, Male
Sex: Female, Male(Participants)Terbinafine 24 WeeksVehicle 24 WeeksTerbinafine 48 WeeksVehicle 48 WeeksTotal
Female34394135149
Male99919493377
08

Study locations

23 sites
  • Dr. Fred D. Youngswick
    Novato, California 94945, United States
  • Dr. Larry Doehring
    Northglenn, Colorado 80234, United States
  • Dr. Robert P. Dunne
    Melbourne, Florida 32935, United States
  • Dr. Mark Ling
    Newnan, Georgia 30263, United States
  • Dr. Jesse Plasencia
    Chicago, Illinois 60632, United States
  • Dr. John Mallory
    Overland Park, Kansas 66215, United States
  • Dr. Jeffrey Conrow
    Topeka, Kansas 66606, United States
  • Dr.Michael Kaye
    Covington, Louisiana 70433, United States
  • Dr. Max Weisfeld
    Baltimore, Maryland 21214, United States
  • Dr. Linda Stein-Gold
    Detroit, Michigan 48202, United States
  • Dr. Anna Glaser
    St. Louis, Missouri 63104, United States
  • Dr. Richard Scher
    New York, New York 10032, United States
  • Dr. Joseph Jorrizo
    Winston Salem, North Carolina 27157, United States
  • Dr. Anne Lucky
    Cincinnati, Ohio 45230, United States
  • Dr. Rich Phoebe
    Portland, Oregon 97210, United States
  • Dr. Patricia Westmorland
    Simpsonville, South Carolina 29681, United States
  • Dr. David Horowitz
    Nashville, Tennessee 37203, United States
  • Dr. Jay Lifshen
    Irving,, Texas 75061, United States
  • Dr. Richard Pollak
    San Antonio, Texas 78229, United States
  • Dr. Patrick Agnew
    Virginia Beach, Virginia 23464, United States
  • Novartis Investigative Site
    Various Cities, France
  • Novartis
    Investigative Site, Germany
  • Novartis Investigative Site
    Various cities, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2007
First posted
Mar 6, 2007
Start
Dec 2006
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Apr 19, 2011
Last update
Apr 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00443820
First posted
Mar 6, 2007
Start date
Dec 2006
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Apr 19, 2011
Last update
Apr 19, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terbinafine

Start the discussion